LiGeR-HN1
Tests whether a two-armed antibody against EGFR and a stem-cell marker can lift first-line immunotherapy results in head and neck cancer.
Phase 2 petosemtamab + pembrolizumab reported ORR ~63% in first-line PD-L1-positive HNSCC (ASCO 2025), far above pembrolizumab's historical ~19-23%. LiGeR-HN1 (first line, includes HPV-positive disease) and LiGeR-HN2 (second line, monotherapy vs chemotherapy) are the registrational trials; interim analyses expected 2026-27.
Setting
Untreated PD-L1-positive recurrent or metastatic HNSCC: petosemtamab + pembrolizumab vs pembrolizumab
Phase
Phase 3
Sponsor
Merus (Genmab)
Registry
Pages like this
not linked directly; found by shared links- ProductFicerafusp alfa
Shares EGFR-directed bispecific + PD-1 blockade, Bispecific antibodies, EGFR, Pembrolizumab.
- TrialFORTIFI-HN01
Shares EGFR-directed bispecific + PD-1 blockade, Bispecific antibodies, EGFR, Pembrolizumab.
- ProductZenocutuzumab
Shares Merus, Bispecific antibodies.
- ProductCetuximab sarotalocan
- TrialEXTREME
- PersonJohn V. Heymach
- PersonKumar Prabhash
- TrialKEYNOTE-048
Shares Pembrolizumab, Head and neck squamous cell carcinoma.